Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Breast Cancer
Phase NA
Enrollment 1060
Locations 55 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of lymphedema two years after randomization.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Axillary lymph node dissection (ALND) — Surgical removal of lymphatic tissue within the anatomical boundaries of the axilla (standard of care in the upfront surgery setting in patients with cN+ BC)
  • Procedure: Axillary radiotherapy (ART) — Axillary irradiation

Primary Outcomes

  • Change in arm-related Quality of Life (QoL) (From baseline to 2 years after randomization)
  • Occurrence of lymphedema (From baseline to 2 years after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-01
Completion: 2037-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1060 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Basel, Switzerland
Principal Investigators:
  • Walter P. Weber, Prof. Dr. med. (PRINCIPAL_INVESTIGATOR) - Breast Surgery Service, University Hospital Basel
Contact Information
Study Contact:
Walter P. Weber, Prof. Dr. med.
+41 61 328 61 49
walter.weber@usb.ch
OPBC project management team
+41 61 55 65134
noax.trial@usb.ch
Annesley Copeland
annesley.w.copeland.civ@health.mil
Walter Reed National Military Medical Center
Interventions
  • Procedure: Axillary lymph node dissection (ALND) — Surgical removal of lymphatic tissue within the anatomical boundaries of the axilla (standard of care in the upfront surgery setting in patients with cN+ BC)
  • Procedure: Axillary radiotherapy (ART) — Axillary irradiation
Study Locations (55 sites)
Walter Reed National Military Medical Center, Bethesda, Maryland 20814 United States
Duke University/Duke Cancer Center, Durham, North Carolina 27710 United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 United States
KH Dornbirn, Dornbirn, Austria
LKH Feldkirch, Feldkirch, Austria
MUI - Univ. Klinik f. Frauenheilkunde Innsbruck, Innsbruck, Austria
Ordensklinikum Linz, Linz, Austria
Medical University Vienna, Department of Gynecology, Vienna, Austria
Medical University Vienna, Department of Surgery, Vienna, Austria
CIUSSS du Centre Ouest-de-l 'Ile-de-Montréal, Montreal, Canada
Eligibility Criteria
Inclusion Criteria at screening: * Written informed consent according to ICH/GCP regulations prior to any trial specific procedures. * Patients ≥ 18 years of age. * Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) American Joint Committee on Cancer/ International Union Against Cancer (AJCC/UICC) stage II-III (all molecular subtypes allowed). * Node-positivity detected by imaging and non-palpable (iN+) and confirmed by pathology. * Node-positivity palpable (cN1-3) and confirmed by pathology. * Occult breast cancer is allowed, if biopsy-proven axillary lymphatic metastasis is present. * Eligible for primary ALND or SLN procedure and either: * Newly diagnosed. * Isolated in-breast recurrence or second ipsilateral breast cancer after previous breast conserving surgery and sentinel procedure and at least 3 years disease free and no prior axillary dissection or axillary RT. * Upfront surgery setting. * Most suspicious axillary lymph node clipped. (If clipping is not part of the routine, this should be done after consent of the patient as a study procedure.) * Ability to complete the QoL questionnaires. * WHO performance status 0-2 * Adequate condition for general anesthesia, breast cancer surgery and radiotherapy. * Adult patients (≥18 years of age). * Women of child-bearing potential are using effective contraception (condom, diaphragm, intrauterine device), are not pregnant or lactating and agree not to become pregnant during trial treatment (until end of RT) and thereafter during the time recommended by the guidelines - also for adjuvant systemic therapies. A negative pregnancy test before registration is required for all women of child-bearing potential. * Men agree not to father a child during trial treatment and for 6 months afterward. Exclusion criteria at screening: * Stage IV breast cancer. * Clinical N3c breast cancer without axillary disease (clinical N3a and clinical N3b are allowed). * Clinical N2b breast cancer (clinical N2a is allowed). * Contralateral breast cancer within 3 years. * Prior axillary surgery (except prior sentinel node procedure in case of in-breast recurrence). * Prior regional radiotherapy. * Neoadjuvant treatment with the exception of bridging therapy given for less than 3 months. * History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from pre-registration with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer. * Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications. Exclusion criteria at randomization (intraoperatively): * Absence of clip in the specimen radiography. * Palpable disease left behind in the axilla after TAS. * No SLN identified in the axilla.
Conditions Guidelines, Diabetes Mellitus Type 2, Ob...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Observational study in physicians regarding their adherence to clinical guidelines (by American Diabetes Association 2025) for the management of type 2 diabetes mellitus and obesity via questionnaire

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Questionnaire regarding the adherence to American Diabetes Association — A questionnaire titled "Physicians' adherence to the current clinical guidelines for the management of patients with type two diabetes mellitus and obesity" was formed, consisting of two sections and 18 closed-ended questions in total. Τhe first part focused on demographics and included four questions, while the second addressed the frequency of adherence to clinical guidelines and consisted of fourteen questions. A 5-point Likert scale, ranging from 'never', 'rarely' (1 - 2 times a month), 'sometimes' (1 - 2 times a week), 'frequently' (3 - 4 times a week) to 'always' (everyday), was used for the 14 questions, aiming to quantify the frequency of implementation. An introductory statement accompanied the questionnaire to provide study details and guarantee anonymous responses.

Primary Outcomes

  • Questionnaire (From start of study (July 2025) until 1 year and half (October 2026))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-01
Completion: 2026-10-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aristotle University Of Thessaloniki
Principal Investigators:
  • Triantafyllos Didangelos, Prof. MD. PhD (PRINCIPAL_INVESTIGATOR) - Aristotle University Of Thessaloniki
Contact Information
Study Contact:
Triantafyllos Didangelos Prof. MD PhD, Professor
+302310994776
didang@auth.gr
Eleni Karlafti, Assistant Professor MD PhD
linakarlafti@hotmail.com
Triantafyllos Didangelos, Professor MD PhD
+302310994776
didang@auth.gr
Medical School of Aristotle University of Thessaloniki
Interventions
  • Other: Questionnaire regarding the adherence to American Diabetes Association — A questionnaire titled "Physicians' adherence to the current clinical guidelines for the management of patients with type two diabetes mellitus and obesity" was formed, consisting of two sections and 18 closed-ended questions in total. Τhe first part focused on demographics and included four questions, while the second addressed the frequency of adherence to clinical guidelines and consisted of fourteen questions. A 5-point Likert scale, ranging from 'never', 'rarely' (1 - 2 times a month), 'sometimes' (1 - 2 times a week), 'frequently' (3 - 4 times a week) to 'always' (everyday), was used for the 14 questions, aiming to quantify the frequency of implementation. An introductory statement accompanied the questionnaire to provide study details and guarantee anonymous responses.
Study Locations (1 sites)
Medical School of Aristotle University of Thessaloniki, Thessaloniki, 54646 Greece
Eligibility Criteria
Inclusion Criteria: * Physicians practicing in Greece * Physicians treating patients with Diabetes Mellitus type 2 and Obesity Exclusion Criteria: * Non Physicians
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase NA
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The main goal of this clinical trial is to determine the effect of flaxseed added to the diet on biochemical parameters and quality of life in patients with Type 2 diabetes mellitus (T2DM). The main questions it aims to answer are: * Does flaxseed supplementation given to T2DM patients for 12 weeks have an effect on biochemical parameters? * Does flaxseed supplementation given to T2DM patients for 12 weeks have an effect on quality of life? Researchers will compare patients with T2DM consume diet added flaxseed to a control group to see if flaxseed effect on biochemical parameters and quality of life. Participants will: * Complete the questionnaire, record the 3-day food consumption and be taken the anthropometric measurements at the beginning and end of the study. * Take diet added 30 g ground flaxseed (intervention group) or only diet (control group) every day for 12 weeks. * Visit the clinic once every 4 weeks for follow-up. * Report the dietary adherence and gastrointestinal symptoms on a phone call once every week.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Flaxseed — 30 g/day for 12 weeks
  • Behavioral: Diet — Diet will be planned to patients with T2DM as a part of their medical nutrition therapy.

Primary Outcomes

  • Evaluation of the effect of flaxseed on fasting blood glucose (mg/dL) (From enrollment to the end of intervention at 12 weeks)
  • Evaluation of the effect of flaxseed on HbA1c (%) (From enrollment to the end of intervention at 12 weeks)
  • Evaluation of the effect of flaxseed on total triglyceride (mg/dL) (From enrollment to the end of intervention at 12 weeks)
  • Evaluation of the effect of flaxseed on total cholesterol (mg/dL) (From enrollment to the end of intervention at 12 weeks)
  • Evaluation of the effect of flaxseed on HDL-cholesterol (mg/dL) (From enrollment to the end of intervention at 12 weeks)
  • Evaluation of the effect of flaxseed on LDL-cholesterol (mg/dL) (From enrollment to the end of intervention at 12 weeks)
  • Evaluation of the effect of flaxseed on quality of life (From enrollment to the end of intervention at 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-30
Completion: 2027-05-12
Eligibility
Age: 19 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ondokuz Mayıs University
Contact Information
Study Contact:
Yasemin ERTAŞ ÖZTÜRK, PhD
+903623121919
yasemin.ertasozturk@omu.edu.tr
Omü Suvam
Interventions
  • Dietary Supplement: Flaxseed — 30 g/day for 12 weeks
  • Behavioral: Diet — Diet will be planned to patients with T2DM as a part of their medical nutrition therapy.
Study Locations (1 sites)
Omü Suvam, Samsun, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Diagnosed with T2DM by a physician * Being between the ages of 19-65 * Having a body mass index (BMI) between 20-35 kg/m2 * Using oral anti-diabetics and not using insulin Exclusion Criteria: * History of gastrointestinal diseases * High consumption of nuts, flaxseeds or sesame seeds (more than one serving per day) * Food allergies or intolerances * Malignancies * Renal failure, liver, other endocrine or inflammatory disorders * Use of lipid-lowering drugs * Smoking and alcohol use * Being pregnant or lactating
Conditions Diabetes Mellitus, Type 1, Diabetes Mell...
Phase PHASE1
Enrollment 124
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it. The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 6 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Drug: LY4057996 SC — Administered SC
  • Drug: LY4057996 IV — Administered IV
  • Drug: Placebo SC — Administered SC
  • Drug: Placebo IV — Administered IV
  • Drug: Degludec SC — Administered SC
  • Drug: Lispro SC — Administered SC
  • Drug: Degludec IV — Administered IV
  • Drug: Pre-study basal insulin SC — Administered SC

Primary Outcomes

  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration (Baseline to Study Completion (Up to 47 Weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-05-16
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
+49 (0) 2131 4018 180
Profil Institut für Stoffwechselforschung
Interventions
  • Drug: LY4057996 SC — Administered SC
  • Drug: LY4057996 IV — Administered IV
  • Drug: Placebo SC — Administered SC
  • Drug: Placebo IV — Administered IV
  • Drug: Degludec SC — Administered SC
Study Locations (1 sites)
Profil Institut für Stoffwechselforschung, Neuss, 41460 Germany
Eligibility Criteria
Inclusion Criteria: Part A for Healthy Participants: * Are overtly healthy as determined by medical evaluation, including medical history, physical exam, laboratory tests, and cardiac screening assessment Part A for Type 2 Diabetes (T2DM) Participants: * Are participants with T2DM diagnosed greater than 1 year before enrollment, * On basal insulin therapy, insulin glargine, insulin detemir, or insulin degludec, greater than 10 units per day for at least 6 months (for Cohort 5 only) * Glycated hemoglobin (HbA1c) 6.5% to 9.5% inclusive at screening Part B * Have Type 1 Diabetes (T1D) for at least 1 year with a fasting C-peptide level of 0.20 nanomole per liter (nmol/L) or less or non-fasting C-peptide level of 0.30 nmol/L or less at screening * HbA1c 6% to 8.5% inclusive at screening Part C * Have T1D for at least 1 year with a fasting C-peptide level of 0.20 nanomole per liter (nmol/L) or less or non-fasting C-peptide level of 0.30 nmol/L or less at screening * HbA1c 6 to 8.5% inclusive at screening All Parts * Have blood pressure of less than 140/90 millimeters of mercury (mmHg) for healthy participants or 150/90 mmHg for participants with diabetes and pulse rate of less than 90 beats per minute (bpm) (supine) * No hypoglycemia unawareness for all Type 1 and Type 2 Diabetes participants Exclusion Criteria: * Have had more than 1 emergency room visit or hospitalization due to poor glucose control (hyperglycemia or diabetic ketoacidosis) within 6 months prior to screening * Have had any episodes of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia), hypoglycemia unawareness, or both within the 6 months prior to screening All Parts * Cardiovascular: no significant history of cardiovascular disease (CVD) * Gastrointestinal: have gastroparesis or have undergone gastric surgery * Hepatic: have acute or chronic hepatitis
Conditions Type 2 Diabetes, Coronary Artery Disease...
Phase Not Applicable
Enrollment 1000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

People with type 2 diabetes have a much higher risk of heart disease. One common problem is when the blood vessels that supply the heart become narrowed or blocked by fatty deposits, called plaque. This makes it harder for blood to reach the heart and can lead to serious problems such as chest pain, heart attacks, or even death. This study will follow people with type 2 diabetes who have already had a special heart scan called a coronary CT angiography. This scan takes detailed pictures of the heart's blood vessels. The goal is to understand how heart disease changes over time in people with type 2 diabetes, by looking at repeat scans and other health information. By learning more about how plaque builds up or gets worse, researchers hope to find better ways to identify which patients are most at risk for future heart problems.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • progression of total coronary plaque volume (mm3) (Between baseline (retrospective) and follow up CCTA (interval 2-5 years).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-06
Completion: 2036-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Horizon Innovative Health Initiative, Novo Nordisk A/S, INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANCA (IBSAL), Cardiology Centers of the Netherlands
Contact Information
Study Contact:
Willem R van de Vijver, MD
+31205662402
w.r.vandevijver@amsterdamumc.nl
Willem R van de Vijver
+3120-5662402
w.r.vandevijver@amsterdamumc.nl
Amsterdam University Medical Centers
Willem R van de Vijver, MD
+3120-5662402
combine-ct@cardiologiecentra.nl
Cardiology Centers of the Netherlands
Interventions
N/A
Study Locations (2 sites)
Amsterdam University Medical Centers, Amsterdam, Netherlands
Cardiology Centers of the Netherlands, Amsterdam, Netherlands
Eligibility Criteria
Inclusion Criteria: * Age over 18 years * Previous completion of CCTA scan for CAD assessment * Diagnosed with Type 2 Diabetes and currently receiving glucose lowering treatment * Sufficient image quality of the CCTA scan (at least 2/3 vessels of sufficient quality for assessment). Exclusion Criteria: * Inability to provide written informed consent * Presence of an unstable condition * Ingeligibility for CCTA acquisition due to severe renal dysfunction (eGFR ≤ 30 mL/min/1.73m²) or known hypersensitivity or contraindication to CT contrast agents * Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator * inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study * Baseline (routine care) CCTA performed \< 2 years or \> 5 years before inclusion

The EMPA-FIT Study

NCT06846411
Recruiting
Conditions Diabetes, Diabetes Mellitus, Type II
Phase PHASE4
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This multicenter, open-label, prospective study randomized 46 drug-naïve adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Empagliflozin 10 mg — The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
  • Drug: Metformin — The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.

Primary Outcomes

  • mean amplitude of glucose excursion (MAGE) (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-01-01
Completion: 2025-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Bundang Hospital
Contact Information
Study Contact:
Ji Young Byun Administrative staff, MS
82-31-787-7035
65423@snubh.org
Soo Lim, MD.
82-10-9766-2706
limsoo@snu.ac.kr
SNUBH
Interventions
  • Drug: Empagliflozin 10 mg — The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
  • Drug: Metformin — The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
Study Locations (1 sites)
SNUBH, Seongnam, South Korea
Eligibility Criteria
Inclusion Criteria: * Participants were eligible if they had T2D with an HbA1c between 6.5% and 10.0%, were between 20 and 75 years of age, and had not received any anti-diabetic medications for at least eight weeks prior to screening. Exclusion Criteria: * individuals with a body mass index (BMI) \<18.5 kg/m² or ≥40 kg/m², clinically significant hepatic impairment (e.g., hepatic cirrhosis, portal hypertension, chronic active hepatitis), or a history of acute cardiovascular events (e.g., coronary artery disease, cerebrovascular disease, peripheral arterial disease) within two months prior to enrollment. Participants with CKD (eGFR \<60 mL/min/1.73 m²) or end-stage renal disease (eGFR \<15 mL/min/1.73 m² or on dialysis) were also excluded. Additional exclusion criteria included uncontrolled hypertension (BP ≥160/100 mmHg), New York Heart Association (NYHA) class III or IV heart failure, chronic oral corticosteroid use (\>30 consecutive days), a history of cancer (except basal cell carcinoma) within the past five years, or significant dyslipidemia (triglycerides \>1,000 mg/dL or LDL cholesterol \>250 mg/dL).
Conditions Obesity & Overweight, Type 2 Diabetes
Phase PHASE1
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: DWRX5003 — Microneedle patch containing Semaglutide
  • Drug: DWC202502 — Semagluide
  • Drug: DWC202503 — Semaglutide
  • Other: DWRX5003P — placebo microneedle patch

Primary Outcomes

  • AUC 0-t (Pre-dose (0 hour) up to 672 hours post-dose)
  • Cmax (Pre-dose (0 hour) up to 672 hours post-dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-05-06
Completion: 2026-11-17
Eligibility
Age: 19 Years – 64 Years
Sex: ALL
Volunteers: true
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Daewoong Pharmaceutical Co. LTD.
Contact Information
Study Contact:
YeaRa Kwak
+8225508317
yeara.kwak@daewoong.co.kr
Seongyeon Hong, Pharm D.
+82-2-740-8872
syhongok@snu.ac.kr
Seoul National University Hospital
Interventions
  • Drug: DWRX5003 — Microneedle patch containing Semaglutide
  • Drug: DWC202502 — Semagluide
  • Drug: DWC202503 — Semaglutide
  • Other: DWRX5003P — placebo microneedle patch
Study Locations (1 sites)
Seoul National University Hospital, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: 1. Healthy adult volunteers aged ≥ 19 and ≤ 65 years at screening 2. Subjects with a body weight ≥ 50.0 kg to ≤ 100.0 kg and a BMI of ≥ 20.0 kg/m2 to ≤ 29.9 kg/m2 at screening 3. Subjects with no congenital disease or chronic disease requiring treatment as well as no pathologic symptoms or findings based on medical examination 4. Subjects who are determined to be eligible for this study based on results of laboratory tests, vital signs, physical examination, 12-lead electrocardiogram (ECG), etc. set and performed according to the nature of the IP at screening 5. Subjects who voluntarily decided to participate in the study and provided written consent to follow subject compliance requirements during the study after receiving a detailed explanation on this study and fully understanding the information Exclusion Criteria: 1. Subjects with past or current medical history of clinically significant hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, digestive, and musculoskeletal diseases: 2. Females who are pregnant (serum-HCG positive) or breast-feeding 3. Subjects with a history of hypersensitivity (e.g., anaphylaxis or angioedema) or clinically significant hypersensitivity to the active ingredient of the IP, pharmaceutical excipients, or other drugs (e.g., GLP-1 receptor agonists) 4. Subjects with a history of skin disease (e.g., burns, skin cancer, etc.) or skin transplant surgery that could affect the absorption of the investigational product 5. Subjects with a history of acute or chronic pancreatitis 6. Subjects with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2) 7. Subjects who are deemed ineligible for participation in the study by the investigator for reasons other than the above inclusion/exclusion criteria etc.
Conditions Pancreatogenic Diabetes Mellitus, Type 2...
Phase Not Applicable
Enrollment 310
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to better understand how the pancreas works in adults with type 2 diabetes. The study focuses on both hormone production (endocrine function) and digestive function (exocrine function) of the pancreas. The main questions it aims to answer are: * Can problems with the pancreas help identify a different type of diabetes called pancreatogenic diabetes? * How are blood markers and pancreas structure related to pancreatic function? Participants will: * Have blood tests to measure glucose, insulin, and other markers * Provide a stool sample to assess digestive function * Undergo an ultrasound examination of the pancreas * Answer questions about digestive symptoms The study will take place during a single visit in outpatient clinics.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Primary Outcomes

  • Prevalence of pancreatogenic diabetes (At single study visit (baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-07
Completion: 2026-12-01
Eligibility
Age: 18 Years – 74 Years
Sex: ALL
Volunteers: false
Enrollment: 310 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: West Kazakhstan Marat Ospanov Medical University
Collaborators: Universitatea de Stat de Medicina si Farmacie Nicolae Testemiţanu
Contact Information
Study Contact:
Mengtay S Makashova
+77058440060
ersultanbeknur@gmail.com
Mengtay Makashova
87058440060
ersultanbeknur@gmail.com
Outpatient clinics of Aktobe region, West Kazakhstan Marat Ospanov Medical University
Interventions
N/A
Study Locations (1 sites)
Outpatient clinics of Aktobe region, West Kazakhstan Marat Ospanov Medical University, Aktobe, Aktobe 030019 Kazakhstan
Eligibility Criteria
Inclusion Criteria: * • adult patients of Kazakh nationality aged 18 to 74 years * diagnosis of T2DM established according to ADA criteria and documented in medical records * disease duration ≤5 years * absence of ketoacidosis episodes within the last 6 months Exclusion Criteria: * positive anti-glutamic acid decarboxylase antibodies (anti-GAD65); * acute or chronic infections affecting metabolic status within the previous 4 weeks; * any history of malignant neoplasms; * pregnancy or lactation; * previously diagnosed type 1 diabetes mellitus or other specific types of diabetes; * severe decompensated chronic diseases; * conditions associated with systemic fibrosis (e.g., liver cirrhosis or autoimmune diseases); * refusal to participate.
Conditions Prediabetes (Insulin Resistance, Impaire...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to determine the effectiveness of using a freeze-dried wild blueberry powder on cardiometabolic health, cognitive function, and gut microbiota composition in adult women with prediabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Wild Blueberry — Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 6 weeks
  • Dietary Supplement: Placebo — Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 6 weeks

Primary Outcomes

  • Blood Glucose (Baseline and 6 weeks)
  • Ambulatory Blood Pressure (Baseline and 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-20
Completion: 2027-09-01
Eligibility
Age: 20 Years – 65 Years
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Georgia State University
Collaborators: Wild Blueberry Association of North America
Principal Investigators:
  • Rafaela G Feresin, PhD (PRINCIPAL_INVESTIGATOR) - Georgia State University
Contact Information
Study Contact:
Rafaela G Feresin, PhD
404-413-1233
berries@gsu.edu
Rafaela G Feresin, PhD
404-413-1233
berries@gsu.edu
Georgia State University
Rafaela G Feresin, PhD
Georgia State University
Interventions
  • Dietary Supplement: Wild Blueberry — Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 6 weeks
  • Dietary Supplement: Placebo — Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 6 weeks
Study Locations (1 sites)
Georgia State University, Atlanta, Georgia 30303 United States
Eligibility Criteria
Inclusion Criteria: * Women aged 20-65 years old * Prediabetes (fasting blood glucose 100-125 mg/dL and/or HbA1c percentage between 5.7-6.4) * Body Mass Index between 25-30 kg/m\^2 Exclusion Criteria: * Allergies to berries * Use of insulin, antidiabetic, antibiotics, and anti-inflammatory drugs * Active cancer, gastrointestinal, renal, thyroid, stage 1 \& 2 hypertension and other cardiovascular diseases, neurological diseases, or severe head injury * Smoking * Consumes greater than 2 alcoholic beverages per day * Consumes antioxidant, probiotic, and prebiotic supplements * Pregnant or Lactating * Actively participating in a weight loss program * Currently taking berry supplements or recently participated in another study taking berry supplements
Conditions Cardiovascular Diseases, Obesity, PreDia...
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

SWIFT-CORE-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, comorbidities, and current symptoms. Site staff may collect vital signs, urine drug screens, blood draws, and urine pregnancy tests. A doctor will review medical history with the participant to determine study suitability via clinical interview. The doctor may reach out to the patient's current treating physicians and pharmacies to determine eligibility for clinical trials.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Blood work — Blood work on some participants to review eligibility for future clinical trials

Primary Outcomes

  • Number of participants who are interested in industry-sponsored clinical research (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-05-30
Completion: 2029-04-17
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brooklyn Clinical Research
Principal Investigators:
  • Ammara Mushtaq, MD (PRINCIPAL_INVESTIGATOR) - Brooklyn Clinical Research
Contact Information
Study Contact:
Ammara Mushtaq, MD
929-203-5879
amushtaq@brooklynclinicalresearch.com
Katherine Azer, MS
929-332-7848
kazer@brooklynclinicalresearch.com
Ammara Mushtaq, MD
929-203-5879
amushtaq@brooklynclinicalresearch.com
Brooklyn Clinical Research
Interventions
  • Other: Blood work — Blood work on some participants to review eligibility for future clinical trials
Study Locations (1 sites)
Brooklyn Clinical Research, Brooklyn, New York 11226 United States
Eligibility Criteria
Inclusion Criteria: 1. Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed. 2. Participant is at least 18 years old. Exclusion Criteria: 1. Participant is pregnant, breast-feeding, or planning to become pregnant. 2. History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results. 3. Moderate or severe substance use disorder within 90 days prior to screen 4. Any condition that in the investigator's opinion makes a participant unsuitable for the study. 5. Currently employed by Swift Clinical Research Group, Inc. or any of its subsidiaries, including Brooklyn Clinical Research, or a first-degree relative of an employee.
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 48
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Arab Americans (AA) face many challenges in diabetes self-management due to the limited educational resources and support available for them. The cultural and linguistic barriers between patients and health care providers lead to poor diabetes management and outcomes. This study (Project Dulce Arabic) is adapted from the Project Dulce, an American Diabetes Association (ADA)-recognized Diabetes Self-Management Education Support (DSMES) program. Project Dulce Arabic comprises both peer-led diabetes education in Arabic and a 3-month text messaging program (Dulce Digital). The main aim of the study is to examine the effectiveness of a more culturally and linguistically appropriate diabetes education program in improving diabetes knowledge, beliefs, and self-management as well as hemoglobin A1C.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Project Dulce + Dulce Digital — Project Dulce is a 5-week curriculum, group diabetes self-management education and support, program delivered by a peer educator in Arabic. The curriculum provides knowledge as well as skills and tools needed to change behaviors and adapt to a life with type 2 diabetes. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring as well as the genetics contribution to diabetes development. It is presented over 5 weeks where participants will learn and practice diabetes self-management skills, and help one another address family, cultural, or health system barriers to managing their diabetes. . Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Arabic.

Primary Outcomes

  • Change from Baseline Diabetes Knowledge at 3 months (3 months)
  • Change from Baseline Diabetes Knowledge at 6 months (6 months)
  • Change from Baseline Health Belief Model Scale at 3 months (3 months)
  • Change from Baseline Health Belief Model Scale at 6 months (6 months)
  • Change in Baseline Self-Efficacy for Diabetes Scale at 3 months (3 months)
  • Change in Baseline Self-Efficacy for Diabetes Scale at 6 months (6 months)
  • Understanding Health Implications of Genomics at 3 months (3 months)
  • Understanding Health Implications of Genomics at 6 months (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-17
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Scripps Whittier Diabetes Institute
Collaborators: National Center for Advancing Translational Sciences (NCATS)
Principal Investigators:
  • Ahmed Khattab, MD (PRINCIPAL_INVESTIGATOR) - Scripps
Contact Information
Study Contact:
Ahmed Khattab, MD
8586782129
akhattab@scripps.edu
Lannea Hand, MS, RDN
720-860-7200
LHand@metrocaring.org
Lannea Hand, MS, RDN
720-860-7200
LHand@metrocaring.org
Metro Caring
Interventions
  • Behavioral: Project Dulce + Dulce Digital — Project Dulce is a 5-week curriculum, group diabetes self-management education and support, program delivered by a peer educator in Arabic. The curriculum provides knowledge as well as skills and tools needed to change behaviors and adapt to a life with type 2 diabetes. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring as well as the genetics contribution to diabetes development. It is presented over 5 weeks where participants will learn and practice diabetes self-management skills, and help one another address family, cultural, or health system barriers to managing their diabetes. . Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Arabic.
Study Locations (2 sites)
San Ysidro Health, El Cajon, California 92020 United States
Metro Caring, Denver, Colorado 80218 United States
Eligibility Criteria
Inclusion Criteria: * Are a participant of Metro Caring * Self-identified Arab * Diagnosed with type 2 diabetes mellitus (T2DM) * HbA1c ≥7.5% in the last 30 days * Able to speak, read, write, and comprehend in English and Arabic * Have access to a cell phone that can receive/send text messages throughout the study Exclusion Criteria: * Pregnant * Are currently participating in another diabetes-related study
Conditions Asthma (Diagnosis), Airway Inflammation,...
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-26
Study Details Design, interventions, and primary outcomes

About This Study

This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. Exploratory thoracic bioelectrical impedance spectroscopy will be assessed alongside standard respiratory tests.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Astaxanthin Oral Capsule — Natural astaxanthin derived primarily from Haematococcus pluvialis, administered orally as three 4 mg capsules daily (total 12 mg/day) with the participant's largest meal for 4
  • Dietary Supplement: Matched Placebo (Capsules) — Matched placebo capsules administered orally once daily as three capsules with the participant's largest meal for 4 weeks.

Primary Outcomes

  • Change in Forced Expiratory Volume in 1 Second (FEV1) (Measured at period-specific baseline and restablishment of baseline after washout period and end of each 4-week treatment period)
  • Change in Fractional Exhaled Nitric Oxide (FeNO) (Measured at period-specific baseline and restablishment of baseline after washout period and end of each 4-week treatment period)
  • Change in Airway Hyperresponsiveness During Hypertonic Saline Challenge (Measured at period-specific baseline and end of each 4-week treatment period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-15
Completion: 2026-07-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Middlesex University
Collaborators: AstaReal, BodyStat Ltd., British Pest Control Association
Principal Investigators:
  • Lygeri Dimitriou (STUDY_DIRECTOR) - Middlesex University
Contact Information
Study Contact:
Ahmet Celen, PhD in Biomedical Science
+447840475597
AC1534@live.mdx.ac.uk
Dr Lygeri Dimitriou
+44 7813 356883
Interventions
  • Dietary Supplement: Astaxanthin Oral Capsule — Natural astaxanthin derived primarily from Haematococcus pluvialis, administered orally as three 4 mg capsules daily (total 12 mg/day) with the participant's largest meal for 4
  • Dietary Supplement: Matched Placebo (Capsules) — Matched placebo capsules administered orally once daily as three capsules with the participant's largest meal for 4 weeks.
Study Locations (1 sites)
Middlesex University, London, Barnet NW4 4BT United Kingdom
Eligibility Criteria
Inclusion Criteria: * Adults 18+ y * Confirmed clinical diagnosis of mild-to-moderate asthma, defined as: * A physician diagnosed asthma condition consistent with BTS/NICE/SIGN (2024) * Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment * No asthma exacerbation requiring systemic corticosteroids within the preceding 6-8 weeks (those with suspected Asthma will be invited to a familiarisation and eligibility session where they will have clinical investigations to assess for asthma and thus be included or excluded) * Ability to demonstrate acceptable and repeatable spirometry in accordance with ATS/ERS standards * Willing to refrain from antioxidant and anti-inflammatory supplementation (e.g. Omega-3, turmeric, NSAID supplements) for the duration of the study * Not consuming high dietary ASTX sources (e.g., frequent salmonid or crustacean intake), assessed at screening * non-smoking and non-vaping * Able and willing to take daily study capsules and attend all required visits * Able and willing to complete home monitoring, including peak flow, air-quality monitoring, and questionnaires * Able to provide written informed consent Exclusion Criteria: * Current smokers or vapers which is associated with chronic airway remodelling, reduce hyperresponsiveness to bronchodilators, and increased neutrophilic inflammation, which can obscure the true effects of asthma-target interventions * Respiratory tract infection within the preceding 4 weeks * Pregnant or lactating individuals * Presence of significant co-morbidities, including CVD or autoimmune or systemic inflammatory diseases * Renal or gastrointestinal disorders that may affect astaxanthin absorption and metabolism * Known allergy or hypersensitivity to ASTX or any components of the study supplement * History of current evidence of alcohol or substance abuse * Participation in another interventional drug or supplement study within the preceding 3 months * Use of medicines with a narrow therapeutic index where supplement interactions may pose risk (e.g., ciclosporin/tacrolimus, warfarin), assessed by investigator * Other significant chronic respiratory disease (e.g., COPD, bronchiectasis)